Patient Support

How can industry stakeholders ensure the quality and supply chain security of existing product?

A prediction of how this shift toward patient-centric care may look.

A secret shopper survey study investigates how an FDA approval impacts patient access to a medication used to combat drug opioid overdose.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

A lack of access could shut out patients in need of maintenance drugs for complex conditions.

What does the legislation mean for patient access leaders, pharma brand managers, and patient service owners? Industry experts weigh in.

Why the integration of AI-enabled solutions has the potential to boost patient support and engagement across numerous patient care settings.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Will the looming changes address the concerns of the patient assistance community?

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.

The agreement focuses on augmenting the patient support experience, including from an adherence perspective.

A study explores the cost-effectiveness of combining methotrexate with various drugs as a way to combat failed methotrexate monotherapy.

Why these programs require a hybrid approach that combines technology and human connection.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.

An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.

A cross-sectional study evaluates the difference in clinical outcomes and demographics between pediatric RSV patients during these multiple timeframes.

A cross-sectional audit study determines how racial and ethnic disparities—among English, Mandarin, and Spanish-speaking patients—can impact access.

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

A retrospective study investigates whether use of these portals can be defined by clinical and sociodemographic data.

The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space.

A retrospective cohort study investigates the characteristics of female patients with localized breast cancer that are associated with this nonpersistence.

A cohort study explores the connection between the rise in Medicare Advantage plan coverage and enrollee satisfaction.

By marrying real-world evidence and AI, pharma stakeholders can identify new opportunities to tailor interventions in a way that is most impactful to patients—helping them overcome roadblocks in initiating and maintaining therapy.

Companies need to alter their thinking to better prioritize patients. Here are three simple yet impactful engagement elements that could help.